KY 234
Latest Information Update: 06 Mar 2008
Price :
$50 *
At a glance
- Originator Kyoto Pharmaceutical Industries
- Class Antiallergics; Antiasthmatics; Antihistamines; Bronchodilators; Imidazoles
- Mechanism of Action Histamine H1 receptor antagonists; Thromboxane A2 synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 06 Mar 2008 Discontinued - Preclinical for Asthma in Japan (unspecified route)
- 06 Jun 2001 No-Development-Reported for Asthma in Japan (Unknown route)
- 15 Nov 1994 Preclinical development for Asthma in Japan (Unknown route)